HC Wainwright Reiterates “Neutral” Rating for Zura Bio (NASDAQ:ZURA)

Zura Bio (NASDAQ:ZURA)‘s stock had its “neutral” rating reiterated by investment analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 10.38% from the stock’s previous close.

Several other research analysts have also weighed in on ZURA. Leerink Partners initiated coverage on Zura Bio in a research report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. Chardan Capital decreased their price objective on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Piper Sandler reiterated an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research report on Friday, October 18th. Finally, Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zura Bio currently has an average rating of “Buy” and a consensus price target of $15.80.

Zura Bio Trading Down 4.0 %

NASDAQ ZURA opened at $4.53 on Monday. The business’s fifty day simple moving average is $4.20 and its 200-day simple moving average is $4.12. Zura Bio has a 52 week low of $2.00 and a 52 week high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). As a group, sell-side analysts forecast that Zura Bio will post -0.49 EPS for the current fiscal year.

Insider Activity

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the sale, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

A number of large investors have recently modified their holdings of the company. Renaissance Technologies LLC lifted its position in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after purchasing an additional 5,900 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after buying an additional 6,412 shares during the last quarter. Forefront Analytics LLC boosted its position in shares of Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after acquiring an additional 7,531 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Zura Bio in the 2nd quarter valued at about $43,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Zura Bio during the 3rd quarter worth about $62,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.